Three broadly-neutralizing monoclonal antibodies (MAbs), b12, 2F5 and 2G12, have been cloned from the B cells of people with on-going HIV-1 infections. These MAbs target envelope proteins of HIV-1 and recent passive-immunization studies using them alone, and in combination, have shown protection of macaques against IV- and mucosal-challenge doses of pathogenic SHIV strains. These results indicate that broadly-neutralizing Abs can produce sterilizing protection against the virus.
Our aim i n designing an AIDS vaccine is to induce the same Ab specificities as b12, 2F5 and 2G12 by active immunization. We are developing peptides that bind tightly and specifically to these MAbs, and plan to use them in a novel immunization strategy to target the production of these same Ab specificities in naive animals. First, we will prime animals with envelope proteins to elicit small amounts of the targeted Abs in the polyclonal response against the whole protein. Next, the MAb-specific peptides will be used to boost the production of only the targeted Abs. Strong T-cell epitopes will be conserved between the Env protein primes and peptide boosts to maintain B-cell responses. MAbs b12, 2F5, and probably 2G12, have very long H3 hypervariable loops that """"""""normal mice"""""""" cannot produce. Thus, we also must use animals that can produce such Abs. We have made the most progress in this approach with the b12 MAb. The peptide, B2.1, binds tightly and specifically to the b12 MAb. The structure of B2.1 in complex with b12 Fab has been elucidated, and is being used to further engineer the B2.1 peptide. Our published studies clearly show that the affinity of b12 is stronger for recombinant B2.1 fused to a larger protein than for its synthetic-peptide analog. Thus, we propose to immunize rabbits, XenoMouseTM animals, and eventually macaques, with phage bearing Env proteins, followed by boosts with phage displaying B2.1 peptide. Serum Ab titers will be tested for the presence of b12-like reactivity, and to understand the molecular and cellular bases of these responses, B-cells bearing anti-B2.1 Abs and anti-gp120 Abs will be isolated by FACS, and their expressed V-genes cloned using RT-PCR on single cells. Cloned Abs having the desired reactivities will be tested for HIV-1-neutralization. The assays should be sensitive enough to detect low levels of b12-like Abs and their B cells. In this way, high-titer responses may be built from initially low ones. We have developed peptide leads for Mabs 2F5 and 2G12, and are doing so for the newly-discovered Mabs 4E10 and Z13; these will be similarly tested.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI049111-03
Application #
6751317
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Bradac, James A
Project Start
2002-06-01
Project End
2007-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
3
Fiscal Year
2004
Total Cost
$243,000
Indirect Cost
Name
Simon Fraser University
Department
Type
DUNS #
208032946
City
Burnaby
State
BC
Country
Canada
Zip Code
V5 1-S6
Breden, Felix; Lepik, Christa; Longo, Nancy S et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 6:e16857
Irving, Melita B; Craig, Lisa; Menendez, Alfredo et al. (2010) Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes. Mol Immunol 47:1137-48
van Houten, Nienke E; Henry, Kevin A; Smith, George P et al. (2010) Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 28:2174-85
Menendez, Alfredo; Calarese, Daniel A; Stanfield, Robyn L et al. (2008) A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J 22:1380-92
Feldman, Anat R; Shapova, Yuliya A; Wu, Sampson S T et al. (2008) Phage display and crystallographic analysis reveals potential substrate/binding site interactions in the protein secretion chaperone CsaA from Agrobacterium tumefaciens. J Mol Biol 379:457-70
Saphire, Erica Ollmann; Montero, Marinieve; Menendez, Alfredo et al. (2007) Structure of a high-affinity ""mimotope"" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 369:696-709
van Houten, N E; Zwick, M B; Menendez, A et al. (2006) Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 24:4188-200
Menendez, Alfredo; Scott, Jamie K (2005) The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem 336:145-57
Menendez, Alfredo; Chow, Keith C; Pan, Oscar C C et al. (2004) Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 338:311-27
Zwick, Michael B; Parren, Paul W H I; Saphire, Erica O et al. (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 77:5863-76